B cell malignancies are hematological disorders that originate from either precursors or mature B cells. Uncontrolled proliferation of B lymphocytes occurs in B cell acute lymphoblastic/chronic lymphocytic leukemia and in both non-Hodgkin and Hodgkin lymphomas. Non-Hodgkin lymphoma is one of the most frequent types of malignancy in the United States, in contrast to Hodgkin lymphoma, and 85% of non-Hodgkin lymphoma originates from the proliferation of B lymphocytes. It is well known that, among high toxicity induced by single or combined therapy, the resistance to treatment and frequent relapsed/refractory disease are also real challenges in the treatment of the complex B-cell non-Hodgkin lymphomas. Thus, new strategies for treatment are urgently needed. Ibrutinib (PCI-32765) is a new therapy for hematological malignancies, affecting the mature B-cell. Recently approved by FDA for the ttreatment of patients with mantle cell lymphoma and chronic lymphocytic leukemia and also designated by European Medicines Agency as an orphan drug for rare conditions, such as diffuse large B-cell lymphoma and follicular lymphoma, Ibrutinib could be a great strategy for the treatment of non-responders to the first-line therapies, with a tremendous potential for elderly patients. Due to the irreversible covalent binding of Ibrutinib with Bruton's tyrosine kinase (Btk), a great efficacy and less toxicity were reported for small lymphocytic lymphoma, prolymphocytic leukemia, multiple myeloma, hairy cell leukemia, Waldenstrom's macroglobulinemia and marginal zone lymphoma. New insights into Ibrutinib's mechanisms of action and resistance to therapy may contribute to the development of novel strategies for personalized therapy of B-cell malignancies and also to a better control of the severe adverse reaction.
ABSTRACT
B cell malignancies are hematological disorders that originate from either precursors or mature B cells. Uncontrolled proliferation of B lymphocytes occurs in B cell acute lymphoblastic/chronic lymphocytic leukemia and in both non-Hodgkin and Hodgkin lymphomas. Non-Hodgkin lymphoma is one of the most frequent types of malignancy in the United States, in contrast to Hodgkin lymphoma, and 85% of non-Hodgkin lymphoma originates from the proliferation of B lymphocytes. It is well known that, among high toxicity induced by single or combined therapy, the resistance to treatment and frequent relapsed/refractory disease are also real challenges in the treatment of the complex B-cell non-Hodgkin lymphomas. Thus, new strategies for treatment are urgently needed. Ibrutinib (PCI-32765) is a new therapy for hematological malignancies, affecting the mature B-cell. Recently approved by FDA for the ttreatment of patients with mantle cell lymphoma and chronic lymphocytic leukemia and also designated by European Medicines Agency as an orphan drug for rare conditions, such as diffuse large B-cell lymphoma and follicular lymphoma, Ibrutinib could be a great strategy for the treatment of non-responders to the first-line therapies, with a tremendous potential for elderly patients. Due to the irreversible covalent binding of Ibrutinib with Bruton's tyrosine kinase (Btk), a great efficacy and less toxicity were reported for small lymphocytic lymphoma, prolymphocytic leukemia, multiple myeloma, hairy cell leukemia, Waldenstrom's macroglobulinemia and marginal zone lymphoma. New insights into Ibrutinib's mechanisms of action and resistance to therapy may contribute to the development of novel strategies for personalized therapy of B-cell malignancies and also to a better control of the severe adverse reaction.
Introduction
According to the World Organization of Health, B cell malignancies are hematological disorders that originate from either precursors or mature B cells. B DISCOVERIES REPORTS 2014, Sep-Dec; 1(1): e3 DOI: 10.15190/drep.2014.3 cell acute lymphoblastic leukemia/lymphoma is characterized by uncontrolled proliferation of immature B lymphocytes, while in B cell chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) mature B cells are implicated. Also, mantle cell lymphoma (MCL), follicular lymphoma (FL), hairy cell leukemia (HCL), prolymphocytic leukemia (PLL), diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma are forms of peripheral B cell malignancies, affecting mature B lymphocytes. These are non-Hodgkin lymphomas 1 . It seems that B cells are also involved in the nodular lymphocyte predominant form of Hodgkin lymphoma (NLPHL), which is a particular subcategory different from the classical Hodgkin lymphoma, in terms of immunophenotype characteristics 2 . Hodgkin lymphoma is rare compared to other cancers, representing 0.6% of all new cancer diagnoses in the US, and 1% of all new cases of neoplasms in the entire world 2, 3 . NLPHL represents only 4-5% of all Hodgkin lymphoma, and a small percent of 3-5% may progress to a diffuse large B cell lymphoma 2 . In contrast, non-Hodgkin lymphoma (NHL) is one of the most common types of malignancy in the USA, after prostate cancer, breast cancer, pulmonary and digestive malignancies, skin melanoma and bladder cancer 4 . 85% of non-Hodgkin lymphoma originates from the proliferation of B lymphocytes and only 15% from T lymphocytes 5 4 . These data highlight the importance of new strategies for treatment, especially for recurrent forms of disease and for elderly patients. Thus, the "accelerated approval" for Ibrutinib by the U.S. Food and Drug Administration -FDA -for treatment of patients with mantle cell lymphoma (November 2013) 6 and for patients with chronic lymphocytic leukemia (February 2014), provides valuable new therapy for non-Hodgkin lymphomas affecting the mature B-cell 7 . Also, European Medicines Agency designated Ibrutinib as an orphan drug for rare conditions, such as diffuse large B-cell lymphoma (November 2013) 8 and follicular lymphoma (January 2014) 9 (see Table 1 ). Several clinical trials have shown less toxicity and a promising efficacy of the "first-in-class" inhibitor, due to the irreversibly covalent binding of Ibrutinib to the Bruton's tyrosine kinase (Btk) [10] [11] [12] . . Btk is important for B lymphocyte development, proliferation and differentiation 15 . Also, Btk is involved in adhesion and migration of B-cells, since the blocking of the tyrosine kinase with Ibrutinib inhibited adhesion and migration of primary CLL cells 16 . The structure of Btk consists of five domains: the N-terminal domain (PH), the Tec homology domain (TH) and the Src homology domains (SH3, SH2, SH1) 14 (see Figure 1) . As reviewed by Hendriks et al., important protein interactions of Btk with various regulators of cell signaling are possible through these five domains, such as the N-terminal PH domain of Btk is responsible for binding of PIP3, BAM11, PKC and FAS, the SH3 domain is important for interaction with SAB (SH3B5), SYK and CBL and the C terminal domain is involved in interaction with FAS, PLCγ2 and caveolin 1 17 . Ibrutinib inhibits Btk through covalent and irreversible binding at C481 residue in the C-terminal domain 13 . Dasatinib, LFM-A13 and ONO-WG-307 are 3 other inhibitors of Btk, but all are characterized by reversible inhibition of Btk. Also, CC-292 seems to inhibit Btk through an irreversible covalent bond at C481, but only a few clinical trials in early phases are described so far 18 . Interestingly, a recent study also highlights the great potential of Ibrutinib in diseases affecting the T-cell, through an irreversible binding to the interleukin-2-inducible kinase (ITK) 19 . . Ibrutinib has a simple treatment algorithm, including the oral administration of 3 capsules x 140 mg (420 mg/per day for chronic lymphocytic leukemia) or 4 capsules x 140 mg (560 mg/per day for mantle cell lymphoma) 20 . Although the encouraging efficacy of Ibrutinib in nonresponders to other therapies and the easy treatment schedule could improve the compliance of the patient, it is very important to carefully monitor the possible severe adverse reactions 21 . A better understanding of mechanisms of action of Ibrutinib is absolutely necessary for a better control of the severe adverse reaction. It is well known that among high toxicity induced by single or combined therapy, the resistance to treatment and frequent relapsed/refractory disease are also real challenges in the treatment of the complex B-cell non-Hodgkin lymphomas 22 . One mechanism incriminated for the resistance to the Ibrutinib treatment seems to be a mutation in C481 residue of Btk, which is an important site for the covalent, irreversible binding of the inhibitor to the kinase 23, 24 . Also, other mutations in downstream signaling of Btk, for example, in PLCγ2, could be involved 23 . The resistance to therapy remains a major concern, and further studies are needed to elucidate the mechanisms responsible for the reduced efficacy of Ibrutinib in some patients. Unfortunately, as reviewed by Stancu et al., Ibrutinib is one of the most expensive long-term treatments used in oncology, and this could also limit its use 25 .
Challenges and future perspectives with Ibrutinib

Up to date clinical trials: safety and efficacy studies
Currently, there are 60 clinical trials for Ibrutinib/ PCI-32765 registered in the database of U.S. National Institutes of Health (ClinicalTrials.gov) 26 (see Table 2 ). Thus, up to date, 46 early studies in Phase I and II proposed to investigate the safety and the efficacy of Ibrutinib alone or in combination with other drugs for a variety of hematological diseases: chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), prolymphocytic leukemia (PLL), follicular lymphoma (FL), mantle cell lymphoma (MCL), diffuse large B-Cell lymphoma (DLBCL), multiple myeloma (MM), hairy cell leukemia (HCL) Waldenstrom's macroglobulinemia (WM) and marginal zone lymphoma (MZL) 26 . Ibrutinib could be a great strategy for treatment of non-responders to the first-line therapies, with a tremendous potential for elderly patients. For example, a recent clinical 11 . Also a high response (68%) was observed after a median follow-up of 15.3 months in 111 patients with relapsed/refractory MCL, also suggesting an efficient drug for patients with MCL that don't respond to other therapies. In this phase II study, the adverse reactions were predominantly mild and moderate: diarrhea (50%), nausea (31%), low appetite (21%), upper respiratory tract infection (23%), but also severe reactions appeared in a few patients: neutropenia (16%), thrombocytopenia (11%) and anemia (10%) 27 . Ibrutinib also showed efficacy in a phase II study performed on 63 patients with WM, with a response rate of 77% in the group of patients presenting the wild-type CXCR4 and 30% in the group with WHIM-like CXCR4 mutations 28 . Also, a phase II study performed on 64 patients with CLL reported lymphocytosis after treatment with one single dose of Ibrutinib. The absolute lymphocyte count increased in more than 40% of patients within 24 hours of starting treatment 29 . More advanced studies in phase III that are currently ongoing or recruiting participants planned to confirm the efficiency and safety of Ibrutinib alone or in combination compared with other drugs for CLL, SLL, MCL, FL, WM and DLBCL 26 . Only one ongoing clinical trial in phase IV is registered in the database of ClinicalTrials.gov, with the estimated date for finalization in April 2014. This study recruited patients with relapsed or refractory MCL after previous therapy in order to monitor the adverse reactions caused by Ibrutinib and to collect safety information about the drug 26 .
Conclusions
The treatment of the complex B-cell non-Hodgkin lymphoma is certainly challenging due to high toxicity induced by single or combined therapy, resistance to treatment and frequent relapsed/refractory disease. Ibrutinib is a promising novel therapy for mature B-cell hematologic lymphomas. It was recently approved by FDA for treatment of patients with mantle cell lymphoma and chronic lymphocytic leukemia, but progresses were also made in several clinical trials for other hematologic malignancies, such as Waldenstrom's macroglobulinemia, multiple myeloma, follicular lymphoma and diffuse large B-cell lymphoma. Clinical trials have shown less toxicity and a promising efficacy of the "first-in-class" inhibitor, due to the irreversibly covalent binding of Ibrutinib with Bruton's tyrosine kinase (Btk). Ibrutinib could be a great strategy for treatment of non-responders to the first-line therapies, with a tremendous potential for elderly patients. A better understanding of mechanisms of action of Ibrutinib may contribute to the development of novel strategies for personalized therapy of B-cell malignancies and also to a better control of the severe adverse reaction. The resistance to therapy is also a major concern, and further studies are needed to elucidate the mechanisms responsible for the reduced efficacy of Ibrutinib in some patients.
